<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00175032</url>
  </required_header>
  <id_info>
    <org_study_id>LAN-0003-0041</org_study_id>
    <secondary_id>U1111-1114-2275</secondary_id>
    <nct_id>NCT00175032</nct_id>
  </id_info>
  <brief_title>A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin</brief_title>
  <official_title>A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal
      complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between
      lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in
      participants with osteoarthritis taking low dose aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to compare the effectiveness of reducing the incidence of
      gastroduodenal ulcers between lansoprazole 30mg QD + naproxen 500mg BID vs celecoxib 200mg QD
      in subjects with osteoarthritis taking low dose aspirin. Approximately 100 sites across the
      U.S. will enroll subjects with normal endoscopic findings and negative H.pylori. The duration
      of the study will be a maximum of 14 weeks including a screening period of up to 2 weeks and
      a 12 week treatment period. Gelusil will be provided for dyspepsia symptom rescue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroduodenal ulcers at final visit</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with GI complications (GI bleeding, perforation and gastric outlet obstruction)</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of each dyspepsia symptom (abdominal pain, nausea, vomiting, heartburn, fullness, and belching) and combined dyspepsia scores.</measure>
    <time_frame>Weeks 4,8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with dyspepsia at weeks 4, 8, and 12 that did not have dyspepsia at baseline.</measure>
    <time_frame>Weeks 4,8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects without dyspepsia at weeks 4, 8, and 12 who had dyspepsia at baseline.</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores of each SODA scale (pain intensity, non-pain symptoms, and satisfaction) for subjects with dyspepsia.</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline SODA scale for subjects with dyspepsia at baseline.</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1045</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Peptic Ulcer</condition>
  <arm_group>
    <arm_group_label>Lansoprazole 30 mg QD + Naproxen 500 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(and added aspirin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib 200 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(and added aspirin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole and naproxen and aspirin</intervention_name>
    <description>Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>Lansoprazole 30 mg QD + Naproxen 500 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib and aspirin</intervention_name>
    <description>Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.</description>
    <arm_group_label>Celecoxib 200 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must require the chronic use of a non-steroidal anti-inflammatory drug for the
             treatment of osteoarthritis.

          -  Must be taking daily aspirin for cardiovascular prophylaxis.

          -  Clinical Laboratory values within normal limits for this population

        Exclusion Criteria:

          -  History of gastric, duodenal or esophageal surgery except simple oversew of an ulcer.

          -  Evidence of uncontrolled, clinically significant disease.

          -  History of cancer within the past 5 years.

          -  Presence of gastroduodenal ulcers, esophageal ulcer or &gt;= 10 gastroduodenal erosions
             during the screening endoscopy. Known history of gastroduodenal ulcer or bleeding
             within the past year. Esophageal stricture requiring dilatation.

          -  Presence of Barrett's esophagus with dysplastic changes.

          -  Systemic disease affecting the esophagus or a history of caustic or physiochemical
             trauma or irradiation to the esophagus.

          -  Sero-tests positive for H. pylori.

          -  Evidence of Zollinger-Ellison syndrome, esophageal varices, cholecystitis, or
             pancreaticobiliary tract disease.

          -  Requires treatment with an excluded medication such as proton pump inhibitors,
             histamine H2 receptor antagonists, antacids, corticosteroids, lithium, fluconazole,
             misoprostol, probenecid, methotrexate, anticoagulants, St. John's wart, dong quai,
             feverfew, garlic, ginger, horse chestnut, red clover or white willow supplements or
             bisphosphonates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1167-74.</citation>
    <PMID>17916545</PMID>
  </results_reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sr. VP Clinical Sciences</name_title>
    <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
  </responsible_party>
  <keyword>Low dose aspirin</keyword>
  <keyword>Peptic Ulcer</keyword>
  <keyword>gastric ulcer</keyword>
  <keyword>duodenal ulcer</keyword>
  <keyword>NSAIDs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Peptic Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

